Naples-headquartered biotechnology company Enveric Biosciences announced positive preclinical results for its lead drug candidate, EB-003, in a severe depression mouse model. In the Open Space Forced Swim Test, company officials said a 30 mg/kg oral dose of EB-003 significantly reduced depression-like behavior within 30 minutes, showing comparable results to the antidepressant Imipramine. A repeat study confirmed the findings and showed no adverse effects from extended, daily dosing over 22 days. EB-003 is part of Enveric’s EVM301 Series, designed to promote neuroplasticity without hallucinations. The results support the company’s plans to file an Investigational New Drug application.